A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

214 Appendix 10 Variation 14 In this variation, the probability of quitting TNF inhibitors in the short term was reduced by 50%. TABLE 146 Variation 14: TNF inhibitors first (1,000,000 patients) Option Cost (£) QSE QALYs QSE Adal 50,542 32 8.9468 0.0053 Etan 64,418 39 9.2912 0.0055 Adal+MTX 50,660 33 8.5290 0.0051 Etan+MTX 64,608 39 8.9364 0.0054 Infl+MTX 49,980 31 8.3593 0.0051 Base 15,336 7 8.3177 0.0050 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 35,206 32 0.6291 0.0054 Etan – Base 49,083 38 0.9735 0.0055 Ad+M – Base 35,325 32 0.2112 0.0052 Et+M – Base 49,273 38 0.6187 0.0054 In+M – Base 34,645 30 0.0416 0.0052 Ad+M – Adal 118 44 –0.4178 0.0054 Et+M – Etan 190 52 –0.3547 0.0057 Etan – Adal 13,876 48 0.3444 0.0056 Et+M – Ad+M 13,948 48 0.4075 0.0055 Ad+M – In+M 680 43 0.1697 0.0052 Et+M – In+M 14,628 47 0.5771 0.0055 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 56,000 55,000 to 56,900 Etan – Base 50,400 49,900 to 51,000 Ad+M – Base 167,000 159,000 to 176,000 Et+M – Base 79,600 78,300 to 81,100 In+M – Base 833,000 666,000 to 1,110,000 Ad+M – Adal Adal alone dominates Adal+MTX Et+M – Etan Etan alone dominates Etan+MTX Etan – Adal 40,300 39,000 to 41,700 Et+M – Ad+M 34,200 33,300 to 35,200 Ad+M – In+M 4,010 3,440 to 4,570 Et+M – In+M 25,300 24,800 to 25,900 TABLE 147 Variation 14: TNF inhibitors third (early RA values) (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 49,271 98 6.3330 0.0150 Etan 61,438 119 6.8631 0.0159 Adal+MTX 49,332 98 6.4770 0.0149 Etan+MTX 61,790 119 6.9684 0.0160 Infl+MTX 49,095 95 6.4474 0.0149 Base 16,462 23 5.4046 0.0138 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 32,809 96 0.9284 0.0148 Etan – Base 44,977 115 1.4585 0.0157 Ad+M – Base 32,871 96 1.0724 0.0148 Et+M – Base 45,329 116 1.5638 0.0157 In+M – Base 32,633 92 1.0429 0.0148 Ad+M – Adal 62 130 0.1440 0.0154 Et+M – Etan 352 154 0.1053 0.0169 Etan – Adal 12,168 143 0.5301 0.0162 continued
TABLE 147 Variation 14: TNF inhibitors third (early RA values) (100,000 patients) (cont’d) © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Et+M – Ad+M 12,458 143 0.4914 0.0162 Ad+M – In+M 238 127 0.0296 0.0154 Et+M – In+M 12,695 141 0.5209 0.0161 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 35,300 34,200 to 36,500 Etan – Base 30,800 30,200 to 31,500 Ad+M – Base 30,700 29,800 to 31,500 Et+M – Base 29,000 28,400 to 29,600 In+M – Base 31,300 30,400 to 32,200 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan 3,340 234 to 6,450 Etan – Adal 23,000 21,500 to 24,600 Et+M – Ad+M 25,400 23,700 to 27,300 Ad+M – In+M Comparison is inconclusive Et+M – In+M 24,400 22,900 to 26,100 TABLE 148 Variation 14: TNF inhibitors third (late RA values) (40,000 patients) Option Cost (£) QSE QALYs QSE Adal 48,510 154 5.6096 0.0234 Etan 60,764 187 6.3362 0.0247 Adal+MTX 48,682 154 5.8713 0.0232 Etan+MTX 61,084 187 6.2842 0.0248 Infl+MTX 48,029 148 5.6453 0.0235 Base 16,478 36 5.3700 0.0217 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 32,032 150 0.2396 0.0223 Etan – Base 44,286 181 0.9662 0.0237 Ad+M – Base 32,204 150 0.5013 0.0225 Et+M – Base 44,606 181 0.9141 0.0239 In+M – Base 31,551 144 0.2753 0.0224 Ad+M – Adal 172 202 0.2617 0.0227 Etan – Et+M 319 240 –0.0521 0.0252 Etan – Adal 12,255 224 0.7266 0.0239 Et+M – Ad+M 12,402 223 0.4128 0.0242 Ad+M – In+M 653 198 0.2260 0.0228 Et+M – In+M 13,054 220 0.6389 0.0241 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 134,000 113,000 to 164,000 Etan – Base 45,800 43,700 to 48,200 Ad+M – Base 64,200 58,900 to 70,600 Et+M – Base 48,800 46,300 to 51,500 In+M – Base 115,000 98,600 to 137,000 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Etan – Et+M Etan+MTX more effective than Etan alone; diff. cost not significant Etan – Adal 16,900 15,700 to 18,200 Et+M – Ad+M 30,000 26,800 to 34,200 Ad+M – In+M 2,890 1,040 to 4,740 Et+M – In+M 20,400 18,900 to 22,300 215
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
Page 129:
The substantial economic impact of
Page 133 and 134:
Summary Effectiveness: principal fi
Page 135 and 136:
inhibitors, although the incrementa
Page 137 and 138:
introduce bias which generally exag
Page 139:
Adalimumab, etanercept and inflixim
Page 143 and 144:
1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146:
46. Young A, Dixey J, Cox N, Davies
Page 147 and 148:
tumor necrosis factor therapy in th
Page 149 and 150:
arthritis: a 12-week, double-blind,
Page 151 and 152:
171. Geborek P, Crnkic M, Petersson
Page 153 and 154:
216. Schotte H, Willeke P, Mickholz
Page 155 and 156:
The Health Assessment Questionnaire
Page 157 and 158:
Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160:
Appendix 3 © Queen’s Printer and
Page 161:
TABLE 69 Studies excluded from clin
Page 164 and 165:
148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167:
150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169:
152 Appendix 4 Infliximab versus pl
Page 170 and 171:
154 Appendix 4 Infliximab plus MTX
Page 173:
Ovid MEDLINE(R) 1966 to February we
Page 177 and 178:
Appendix 8 © Queen’s Printer and
Page 179 and 180: TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184: TABLE 82 Brennan et al., 2004 160
Page 185 and 186: TABLE 83 Kobelt et al., 2004 163 (c
Page 187 and 188: TABLE 85 Bansback et al., 2005 166
Page 189: TABLE 86 Kobelt et al., 2005 167 (c
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 221 and 222: TABLE 132 Variation 10: TNF inhibit
Page 229: TABLE 144 Variation 13: TNF inhibit
Page 243: TABLE 165 Variation 18: TNF inhibit
Page 247 and 248: Volume 1, 1997 No. 1 Home parentera
Page 249 and 250: No. 3 Screening for sickle cell dis
Page 251 and 252: No. 25 A rapid and systematic revie
Page 253 and 254: No. 11 First and second trimester a
Page 255 and 256: No. 23 Clinical effectiveness and c
Page 257 and 258: No. 28 Outcomes of electrically sti
Page 259: No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263: 246 Health Technology Assessment Pr
Page 264: 248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?